New Advances Against Drug-Resistant HIV

Good news on the HIV front: a new investigational drug, Etravirine (a non-nucleoside reverse transcriptase inhibitor) has been shown in combination with Prezista (a protease inhibitor) to be very effective against advanced multi-drug resistant HIV. The just-concluded study took place in 18 countries including at 30 sites in the United States. Prezista is already approved for use in the U.S. and now Etravirine is expected to be fast-tracked for the same. The findings of the study will be presented at this month's International AIDS Conference in Sydney.